Ready To Welcome To...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$19.57 0.13 | 0.67%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -220.87M | -123.60M | 85.25M | -80.01M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -67.00K | 373.00K | 3.18M | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 816.00K | 2.10M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.66M | 2.39M | -1.68M | -4.56M |
| (Decrease) Increase In Other Current Liabilities | 10.38M | 5.11M | -850.00K | -2.91M |
| (Increase) Decrease In Other Working Capital | 6.83M | 1.74M | -112.28M | 15.98M |
| Other Non-Cash Items | 39.08M | 56.11M | 25.84M | 13.27M |
| Net Cash From Continuing Operations | -153.68M | -53.26M | 6.42M | -51.90M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -153.68M | -53.26M | 6.42M | -51.90M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 44.50M | 0.00 | 0.00 | 22.43M |
| Purchases of Property, Plant & Equipment | -5.06M | -2.12M | -2.04M | -3.51M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -89.55M | 0.00 | 0.00 | -7.60M |
| Other Cash from Investing Activities | -289.00K | 0.00 | 0.00 | -50.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -50.40M | -2.12M | -2.04M | 11.27M |
| Issuance of Debt | 0.00 | 4.38M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 22.99M | 255.93M | 60.93M | 58.94M |
| Repayment of Long-Term Debt | -1.45M | -1.47M | -2.04M | -1.49M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -4.34M | -827.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 17.20M | 258.01M | 58.88M | 57.45M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -186.88M | 202.63M | 63.27M | 16.82M |
Portfolios with ARIA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ProSteven Cohen - SAC Capital
- ProDaniel Loeb - Third Point
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
Latest ARIA Headlines from TheStreet
- Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Winner 05.22.13 | 05:05 pm
- Ariad Stock Falls On Unusually High Volume (ARIA) 05.16.13 | 12:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine 04.04.13 | 10:04 am
- Ariad Stock Falls On Unusually High Volume (ARIA) 04.03.13 | 02:04 pm
- The Survey Says: Ariad's Leukemia Drug Is Toxic 04.03.13 | 01:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day 03.28.13 | 05:03 pm
- Ariad Pharma Falls On Weak Leukemia Drug Prescriptions 03.27.13 | 12:03 pm
Press Releases for ARIA
- ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union - Business Wire 03.22.13 | 08:03 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.20.13 | 07:03 am
- ARIAD To Present At Barclays Global Healthcare Conference - Business Wire 03.06.13 | 07:03 am
- ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.28.13 | 07:02 am
- ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013 - Business Wire 02.25.13 | 07:02 am
- Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire) - Business Wire 02.21.13 | 02:02 am
- ARIAD To Present At The RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 07:02 am
- ARIAD To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.08.13 | 07:02 am
- ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results - Business Wire 02.05.13 | 07:02 am
- ARIAD Announces Completion Of Public Offering - Business Wire 01.29.13 | 04:01 pm
Partner Headlines for ARIA
- Pre-Market Earnings Report for February 25, 2013 : LOW, FE, HTZ, DCI, KOS, ARIA, DDD, BGC, CTB, CWH, HL, DNDN - NASDAQ 02.22.13 | 09:02 pm
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, $32 PT - Benzinga 12.07.12 | 09:12 am
- Data Published on ARIAD Candidate - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- ARIAD Seeks Ponatinib Approval - Analyst Blog - Zacks 10.02.12 | 06:10 pm
- ARIAD Partner Withdraws PMA - Analyst Blog - NASDAQ 09.19.12 | 08:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - NASDAQ 08.31.12 | 10:08 pm
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - Zacks 08.31.12 | 06:08 pm
